What Pivotal bioVenture Partners does

Pivotal bioVenture Partners is a San Francisco-based life sciences venture capital firm founded in 2017, operating as the flagship private investment vehicle of the Pivotal Life Sciences platform. The firm invests in transformative therapeutic-focused healthcare companies developing high-impact therapeutics to address major unmet medical needs, with disclosed activity concentrated in clinical-stage biotechnology (e.g., respiratory, inflammatory disease). Core coverage spans North America and Europe, supported by physical offices in San Francisco and Cambridge (Boston).

The firm operates within a three-arm Pivotal Life Sciences structure that also includes Pivotal bioVenture Partners China — a venture-building operation with offices in Shanghai and Hong Kong serving the Greater China region — and Pivotal Public Equity, which targets publicly traded life sciences companies. This structure allows the platform to deploy capital across private and public markets and across major biotech geographies. The firm is led by three managing partners (Heather Preston, Robert Hopfner, Vincent Cheung) and operates with a headcount of 11-50 employees.

As a venture capital entity, Pivotal bioVenture Partners earns revenue through traditional VC economics: management fees on committed fund capital and carried interest on successful portfolio exits. Recent disclosed investment activity includes leading an $80 million Series A for Mosanna Therapeutics (June 2025) and participating in Evommune's $115 million Series C (October 2025). The firm co-invests with other institutional investors such as EQT Life Sciences, consistent with standard syndication practices in the biotech VC market.

Name

Pivotal bioVenture Partners

Legal name

Pivotal Life Sciences

Website

https://pivotalbiovp.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Pivotal bioVenture Partners is a San Francisco-based life sciences venture capital firm founded in 2017, investing in transformative therapeutic-focused biotech companies across North America, Europe, and Greater China.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (525990), Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital investing
• Biotech venture capital
• Life sciences investment
• Therapeutics development funding
• Healthcare startup funding

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Core offering

Pivotal bioVenture Partners is a life sciences venture capital firm that invests in early-stage biotechnology companies developing transformative therapeutics to address major unmet medical needs. Established in 2017, the firm deploys venture capital into healthcare companies across North America and Europe, and operates a dedicated Greater China venture building arm alongside a public equities strategy targeting publicly traded life sciences companies.

Product overview

Pivotal Life Sciences is a global healthcare investment firm operating across three distinct investment arms: Pivotal bioVenture Partners (a life sciences venture capital firm investing in transformative therapeutic-focused healthcare companies across North America and Europe, established in 2017), Pivotal bioVenture Partners China (specializing in venture building for innovative healthcare companies in the Greater China region), and Pivotal Public Equity (focusing on publicly traded life sciences companies). The firm supports companies developing high impact therapeutics to address major unmet medical needs.

Differentiator

Problem solved

Functional benefit

Products and services

• Pivotal bioVenture Partners A venture capital fund that invests in transformative therapeutic-focused healthcare companies across North America and Europe. Target customers are early-stage biotech companies developing high-impact therapeutics to address major unmet medical needs.
• Pivotal bioVenture Partners China A venture building operation that partners with innovative life sciences and healthcare companies in the Greater China region. Target customers are healthcare companies in Greater China seeking venture building partnership and capital.
• Pivotal Public Equity An investment platform that captures opportunities with publicly traded life sciences companies seeking to scale and grow. Target customers are publicly traded life sciences companies seeking growth capital.

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• OrbiMed Advisors: One of the largest healthcare-dedicated investment firms globally with multi-strategy private and public equity funds focused on biotechnology, medical devices, and diagnostics. Comparable to Pivotal as a sector-specialist with a full lifecycle biotech investment platform.
• ARCH Venture Partners: Pioneer biotech venture firm with large, multi-fund platform investing across all stages of therapeutics development. Comparable to Pivotal as a long-tenured sector specialist with deep biotech focus.
• Baker Bros. Advisors: Long-only biotech-focused investment adviser managing both public and private life sciences portfolios. Comparable to Pivotal's hybrid private/public life sciences platform.
• Andreessen Horowitz (a16z Bio + Health): Multi-stage venture firm with a dedicated Bio + Health fund investing across therapeutics, digital health, and biotech. Comparable as a sector-focused VC platform, though significantly larger and broader than Pivotal.

Direct peers

• RA Capital Management: Boston-based healthcare-focused crossover fund investing across public and private biotech companies with a research-driven, sector-specialist thesis. Directly comparable to Pivotal's biotech-focused, multi-stage investment approach.
• Atlas Venture: Early-stage life sciences venture firm building biotech companies from inception, primarily in North America and Europe. Comparable to Pivotal in its therapeutic-focused, early-stage Series A orientation.
• Versant Ventures: Healthcare-focused venture firm with offices in North America and Europe that builds and invests in early-stage biotech companies. Closely comparable to Pivotal's NA/EU focus on transformative therapeutics.
• 5AM Ventures: Early-stage venture firm exclusively focused on life sciences with offices in San Francisco and Boston. Direct peer in therapeutics venture capital with comparable geographic footprint.
• EQT Life Sciences: European life sciences venture firm investing across biotech and medtech stages. Directly comparable given documented co-investment alongside Pivotal in Mosanna Therapeutics' $80M Series A.

Regional players

• Hillhouse Capital: Asia-based investment firm with a dedicated healthcare/biotech practice covering China and global markets. Comparable to Pivotal bioVenture Partners China for cross-border Greater China life sciences investing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments45 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pivotal bioVenture Partners